ENA Respiratory and the University of Maryland have announced plans to partner on a Phase II study of INNA-051 for the prevention of illness due to viral respiratory infections. 

Dr Justin Ortiz, Professor of Medicine at the University of Maryland School of Medicine’s Center for Vaccine and Global Development (CVD), will be Principal Investigator. 

INNA-051 is being developed as a once-a-week nasal dry powder product to reduce the impact of viral respiratory infections and prevent severe complications in at-risk populations. 

INNA-051 is a potent agonist of toll-like receptor 2/6 (TLR2/6) which plays a key role in recognising pathogens and potentiating innate immune responses.  

It has demonstrated accelerated virus clearance and stimulation of antiviral host defences, including IFN Type I & III responses, in a Phase IIa proof-of-principle study using a human influenza-challenge model. 

The new study will test INNA-051 in generally healthy adult participants who are at increased risk to viral respiratory infections during the North American 2025/26 fall/winter season. 

“Partnering with CVD and having Professor Justin Ortiz as one of the Principal Investigators for this Phase II trial is a significant step for ENA Respiratory,” said Christophe Demaison, CEO of ENA Respiratory. “We now look forward to working together to deliver the next step in the development of what we believe could be a significant new approach to reducing the enormous burden of respiratory viral diseases.” 

Dr Ortiz said: “Viral respiratory infections are a major global public health problem and there is a clear need for new approaches to tackle the complications that lead to significant morbidity and mortality. We are excited to be partnering with ENA Respiratory on this important study to test their new approach for boosting the body’s natural host defence pathways.”

Diana Spencer, Senior Digital Content Editor, DDW